Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

HC Wainwright & Co. Upgrades Diffusion Pharmaceuticals to Buy, Announces $9.5 Price Target

Author: Benzinga Newsdesk | August 16, 2022 05:26am
HC Wainwright & Co. analyst Swayampakula Ramakanth upgrades Diffusion Pharmaceuticals (NASDAQ:DFFN) from Neutral to Buy and announces $9.5 price target.

Posted In: DFFN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist